1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Slides:

Advertisements

Similar presentations

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.

Advertisements

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

FDA Perspective Sally Loewke, M.D. Acting Division Director

News You Can Use… Pete Koval, PharmD Laura Evington, PharmD candidate Cone Health Family Medicine November 2014.

Badrul A. Chowdhury, MD, PhD

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Methylphenidate Transdermal System (MTS): Safety Issues Robert Levin, M.D. Medical Officer Division of Psychiatry Products Center for Drug Evaluation and.

Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

AA-7-1 René Belder, MD Executive Director Clinical Development and Life Cycle Management Cardiovascular / Metabolics 7asdf.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

1 Non-Sedating Antihistamines Rx-to-OTC Switch NDAC & PADAC Joint Meeting May 11, 2001 François Nader, MD Senior Vice-President Medical & Regulatory Affairs,

DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENATIONS.

 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee Meeting September 15, 2004

1 One Year Post Exclusivity Adverse Event Review: Topotecan Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

History of Pediatric Labeling

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

1 One Year Post Exclusivity Adverse Event Monitoring as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Dr.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.

Modafinil for the Treatment of ADHD Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

ASENT/ISCTM, Feb 23 rd, 2012, Washington DC, USA Pharmaceuticals & Medical Devices Agency Pediatric Drug Development for Neuro-Psychiatric Diseases Yoshiaki.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.

Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.

Presentation transcript:

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004 Jane Filie, MD Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Moiety: Allegra® (fexofenadine hydrochloride) Therapeutic Category: Anti-histamine Sponsor: Aventis Pharmaceuticals Inc. Indications: –Seasonal allergic rhinitis: dosage for adults and children ≥ 12 years of age 60 mg twice daily, or 180 mg once daily; children 6-11 years of age 30 mg twice daily –Chronic idiopathic urticaria: dosage for adults and children ≥ 12 years of age 60 mg twice daily; children 6-11 years of age 30 mg twice daily Original Market Approval: July 25, 1996 Pediatric Exclusivity Granted: January 27, 2003

3 Clinical Studies for Exclusivity A total of 415 children ≥ 6months and < 6 years of age with allergic rhinitis were given fexofenadine in three pivotal studies. –Phase 1 PK study characterizing the dose for children 6 months to 2 years of age. –Phase 3 study assessing safety and tolerability in two groups: ≥ 6 months to 2 years of age and ≤ 10.5kg ≥ 6 months to 2 years of age and ≥ 10.5 kg A previous safety and tolerability study on children ≥ 2 to <6 years of age was also submitted. Adverse events for fexofenadine occurred at similar frequencies as placebo and there was no evidence of a new safety signal.

4 Clinical Studies for Exclusivity Efficacy was extrapolated from adult data as the disease course and pathophysiology of allergic rhinitis and chronic idiopathic urticaria as well as the drug’s effect are similar in children and in adult patients. The studies conducted on children ≥ 6 months and <2 years of age, and 2 years to < 6 years of age utilized fexofenadine powder mixed with applesauce or rice cereal. There is no marketable age appropriate formulation for children ≥ 6 months to < 6 years of age.

5 Drug Use Trends in Outpatient Settings: Fexofenadine Fexofenadine is the leading prescription non-sedating anti-histamine in the market since loratadine became OTC in The total number of fexofenadine products dispensed increased from approximately 20.8 million in 2000 to 29.6 million in Pediatric patients (age 1 – 16 years) accounted for approximately 8.3% of total U.S. prescriptions of fexofenadine dispensed in 2003 (2.5 million). 1, 3* The most common diagnoses associated with use in pediatric patients (age 0-16 yrs) in 2003 were allergic rhinitis (approx 37%) and allergic disorder (approx 11%). 2 1 IMS Health, National Prescription Audit Plus , Jan 2000 – Dec 2003, Data Extracted Apr IMS Health, National Disease and Therapeutic Index , CD-Rom, 6 Year Jan 2000 – Dec 2003, Data Extracted Apr AdvancePCS  Dimension Rx, Data Extracted Apr 2004 **Calculation based on application of proportions of pediatric fexofenadine prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of fexofenadine prescriptions dispensed nationwide to pediatric population.

6 Adverse Events From Pediatric Clinical Trials Included in the Label Greater than 2%: Headache Accidental injury Coughing Fever Pain Otitis media Upper resp. infection Less than <1%: Insomnia Nervousness Sleep disorders Rare rash Urticaria Pruritus Hypersensitivity reactions

7 Adverse Event Reports: Fexofenadine 1/27/03 – 2/27/04 Total number of reports, all ages: –158 reports (84 U.S.) Pediatric reports: –8 unduplicated reports including 2 with serious outcomes one hospitalization one life threatening No pediatric deaths

8 Unlabeled Pediatric Adverse Events: Fexofenadine 1/27/03 – 2/27/04 Psychosis exacerbation, suicidal ideation, depression Seizure Visual disturbances Abnormal liver function Urinary tract infection/fungal Non-accidental overdose of multiple drugs and prolonged QT Prematurity Maternal exposure Medication error

9 Individual Pediatric Adverse Event Reports A 15 year old with schizoaffective disorder and attention deficit disorder experienced life threatening exacerbation of psychosis, suicidal ideation, and depression. Patient also on Geodon, Effexor, Concerta. Symptoms resolved in 4-5 days after discontinuation of fexofenadine.

10 Individual Pediatric Adverse Event Reports (cont.) Seizure in a 13 year old on concomitant medications including sertraline, olanzapine, minocycline and bupropion (has warning about the potential to cause seizures). A 7 year old patient reported seeing “black dots, white foam, and bubbles,” and loss of color vision after one day on fexofenadine. Symptoms improved 3 days after discontinuation of drug.

11 Individual Pediatric Adverse Event Reports (cont.) A 10 year old patient developed a bacterial urinary tract infection and abnormal liver function tests after receiving fexofenadine for 1 week. The child had received another drug that is labeled for hepatic function impairment before the event. The child recovered after fexofenadine was discontinued. A 16 year old patient developed a fungal urinary tract infection and pyelonephritis. The patient was taking multiple medications for depression and gastritis. The patient was hospitalized.

12 Individual Pediatric Adverse Event Reports (cont.) A 13 year old attempted suicide with intentional overdose of fexofenadine acetaminophen, metoclopramide, and tramadol. QT prolongation to 441 msec was observed but normalized the following day.

13 Individual Pediatric Adverse Event Reports (cont.) Baby born preterm at 27 weeks of gestation, small for gestational age with abnormal alpha-1- fetoprotein born by cesarean section to a mother with pre-eclampsia. Mother also on concomitant medications during pregnancy (allergy shots, vitamins, Augmentin). Refill of prescription for Allegra-D filled with Zyrtec-D. No adverse event reported.

14 Closing Observations: Fexofenadine There were few pediatric adverse event reports during the one-year post pediatric exclusivity period. FDA will continue its routine monitoring of adverse event reports in all populations.